Background: A Quality Improvement Educational Intervention (QIEi) was developed to improve disease management for T2D patients with CVD/CKD who may benefit from SGLT-2i/GLP-1RA. An aim was to assess the change in the number of prescriptions of these two medication classes.

Methods: The QIEi was deployed at two practice sites of a large Integrated Health Care System. A team was formed comprising of endocrinologists and 3 PCPs at each site. EHR data review confirmed the gaps and guided QI project discussions. Process improvements and communication strategies were implemented. All the PCPs at the practice sites (N=18 each) received education on these two medication classes. Cased-based and didactic CME accredited webinars designed to help improve knowledge, decision-making and implement best practices were made available for on-demand participation across the health care system.

Results: Prescription rates of SGLT-2i and GLP-1RA at the intervention (N=4247 baseline, 4033 follow up) and non-intervention sites (N=98637 baseline, 91923 follow up) were obtained pre- and 6 months post QIEi. Odds of GLP-1RA prescription dropped by 2% (p=0.75) at the intervention sites and by 6% (p<0.001) at the non-intervention sites. The decrease was not significantly different across sites (p=0.41). There was a small increase in SGLT2i prescription at the intervention sites (p=0.90), while the odds of use decreased by 3% (p=0.017) at non-intervention sites. This was not significantly different across sites (p=0.54).

Conclusion: No meaningful change in prescriptions post-QIEi at the two intervention sites was observed. While it did improve knowledge and engagement, it did not translate into prescription increases. Perhaps more time is needed to observe system-wide changes and/or other factors need to be considered to increase prescriptions for this patient population. Further studies investigating prescribing barriers are warranted.

Disclosure

P.Rao: None. V.Makin: Speaker's Bureau; Bayer Inc. S.Kawczak: None. P.Lazure: None. J.F.Bena: None. P.Mcfadden: None. G.Jacobs: None. K.M.Pantalone: Consultant; AstraZeneca, Bayer Inc., Corcept Therapeutics, Diasome, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi, Research Support; Bayer Inc., Merck & Co., Inc., Novo Nordisk, Twin Health, Speaker's Bureau; AstraZeneca, Corcept Therapeutics, Merck & Co., Inc., Novo Nordisk.

Funding

Eli Lilly and Company; Merck & Co., Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.